Bio Light Israeli Life Sciences Investments Ltd. (TASE:BOLT) share jumped over 20% to NIS 1.42 per share after the company reported to the Tel Aviv Stock Exchange that its subsidiary OBEcure Ltd. had successfully completed its BET-209 trial to add a 144 gram daily dose of anti-obesity drug Histalean to its anti-psychotic drug Zyprexa, which is produced by Eli Lilly to treat schizophrenia and manic depression.
According to preliminary results, the trial's targets were achieved and the safety of using the drug was proven in a dosage three times the usual level. The drug lowered to a statistically significant extent the weight gain associated with taking Zyprexa.
Zyprexa is known as an extremely efficient drug in treating schizophrenia and manic depression but its side-effects frequently include a rapid and significant rise in weight of most patients (up to 10 kilograms over 16 weeks).
The company believes that the trial results will enable it to open a dialogue with the US Food and Drug Administration (FDA) and the corresponding bodies in the EU, Japan and Far East.
Bio Light's shares are up 88.6% in 2009.
Published by Globes [online], Israel business news - www.globes-online.com - on June 14, 2009
© Copyright of Globes Publisher Itonut (1983) Ltd. 2009